Earnings History Data for Neurocrine Biosciences, Inc. (NBIX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company's neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
30-10-2024	PM		NBIX	Neurocrine Biosciences, Inc.	11,730	1.24	1.47	0.82		124.41	8.22 (7.07%)	125.44	9.25 (7.96%)	103.63 - 157.98	2,243,924	790,000	23,616
Neurocrine Biosciences Q3 2024 Earnings Preview [10/29/2024 11:54 AM] Neurocrine Biosciences bats Q3 revenue estimates, revises guidance [10/30/2024 7:07 AM] Neurocrine stock jumps 9% on strong Ingrezza sales, stock buyback [10/30/2024 10:36 AM] Neurocrine: Q3 Earnings Snapshot [2024-10-30 07:07AM] Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance [2024-10-30 07:00AM]
01-08-2024	PM		NBIX	Neurocrine Biosciences, Inc.	14,210	0.63	1.15	0.95	Neurocrine Biosciences Non-GAAP EPS of $1.63 beats by $0.10, revenue of $580M beats by $33.4M [8/1/2024 7:06 AM]	153.66	12.09 (8.54%)	153.00	11.43 (8.07%)	99.98 - 157.98	1,703,989	790,000	6,964
Neurocrine Biosciences Q2 2024 Earnings Preview [7/31/2024 12:20 PM] Neurocrine Biosciences Non-GAAP EPS of $1.63 beats by $0.10, revenue of $580M beats by $33.4M [8/1/2024 7:06 AM]
01-05-2024	PM		NBIX	Neurocrine Biosciences, Inc.	13,820	0.42	1.04	-0.79	Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M [5/1/2024 7:12 AM]	143.16	5.62 (4.09%)	142.00	4.46 (3.24%)	89.04 - 148.37	1,326,079	790,000	1,118
Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M [5/1/2024 7:12 AM] Neurocrine Biosciences Q1 2024 Earnings Preview [4/30/2024 11:50 AM] Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle [5/1/2024 12:47 PM]
07-02-2024	PM		NBIX	Neurocrine Biosciences, Inc.	13,920	1.44	1.13	0.88	Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M [2/7/2024 7:01 AM]	136.41	-6.56 (-4.59%)	141.00	-1.96 (-1.37%)	89.04 - 143.35	1,371,213	710,000	4,216
Neurocrine Biosciences Q4 2023 Earnings Preview [2/6/2024 1:15 PM] Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.03, revenue of $515.2M misses by $3.19M [2/7/2024 7:01 AM]
31-10-2023	PM		NBIX	Neurocrine Biosciences, Inc.	10,540	0.82	0.90	0.69	Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M [10/31/2023 7:07 AM]	110.90	3.77 (3.52%)	0.0	0.0 (0.00%)	89.04 - 129.29	1,166,220	580,000	0
Neurocrine Biosciences Q3 2023 Earnings Preview [10/30/2023 12:34 PM] Neurocrine Biosciences Non-GAAP EPS of $1.54 beats by $0.21, revenue of $498.8M beats by $19.77M [10/31/2023 7:07 AM]
01-08-2023	PM		NBIX	Neurocrine Biosciences, Inc.	10,030	0.95	0.77	-0.18	Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M [8/1/2023 7:18 AM]	103.44	1.55 (1.52%)	0.0	0.0 (0.00%)	89.04 - 129.29	1,082,387	860,000	0
Neurocrine Biosciences Q2 2023 Earnings Preview [7/31/2023 2:33 PM] Neurocrine Biosciences Non-GAAP EPS of $1.25 beats by $0.13, revenue of $452.7M beats by $4.72M [8/1/2023 7:18 AM]
03-05-2023	PM	7:30 AM ET (May 3)	NBIX	Neurocrine Biosciences, Inc.	10,140	-0.79	0.28	0.14	Neurocrine Biosciences Non-GAAP EPS of -$0.51, revenue of $420.4M beats by $11.33M [5/3/2023 7:42 AM]	98.54	-4.91 (-4.75%)	105.00	1.55 (1.50%)	75.25 - 129.29	1,645,064	620,000	3,032
Neurocrine Biosciences Q1 2023 Earnings Preview [5/2/2023 1:07 PM] Neurocrine Biosciences Non-GAAP EPS of -$0.51, revenue of $420.4M beats by $11.33M [5/3/2023 7:42 AM]
06-02-2023	PM	7:30 AM ET (Feb 6)	NBIX	Neurocrine Biosciences, Inc.	10,380	0.88	1.15	-0.08	Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04M [2/6/2023 7:33 AM]	105.06	-4.97 (-4.52%)	110.03	0.0 (0.00%)	75.25 - 129.29	1,425,730	860,000	1,475
Neurocrine Biosciences Non-GAAP EPS of $1.24 misses by $0.20, revenue of $412M beats by $3.04M [2/6/2023 7:33 AM]
01-11-2022	PM	7:30 AM ET (Nov 1)	NBIX	Neurocrine Biosciences, Inc.	11,050	0.69	0.84	0.23	Neurocrine Biosciences Non-GAAP EPS of $1.08 misses by $0.04, revenue of $387.9M beats by $11.15M [11/1/2022 7:32 AM]	119.85	4.73 (4.11%)	115.12	0.0 (0.00%)	71.88 - 123.47	1,662,066	830,000	113,692
Neurocrine Biosciences Non-GAAP EPS of $1.08 misses by $0.04, revenue of $387.9M beats by $11.15M [11/1/2022 7:32 AM] Neurocrine stock jumps on raised sales outlook for Ingrezza, Q3 revenue up 31% [11/1/2022 12:14 PM]
04-08-2022	AH	4:00 PM ET (Aug 4)	NBIX	Neurocrine Biosciences, Inc.	9,110	-0.18	0.56	0.43	Neurocrine Biosciences Non-GAAP EPS of $0.84 misses by $0.05, revenue of $378.2M beats by $34.75M [8/4/2022 4:15 PM]	104.04	8.11 (8.45%)	104.04	0.0 (0.00%)	71.88 - 108.02	2,139,771	540,000	9,854
Neurocrine Biosciences Non-GAAP EPS of $0.84 misses by $0.05, revenue of $378.2M beats by $34.75M [8/4/2022 4:15 PM] Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial [8/5/2022 5:21 AM] Neurocrine stock rises as Q2 revenue soars 31% Y/Y, raises sales outlook for Ingrezza [8/5/2022 12:45 PM] Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance [Aug-04-22 04:01PM] Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up [Aug-04-22 01:38PM] Dow Jones Futures: Jobs Report Will Test 'Soft Landing' Market Rally; Tesla Stock Split Approved [Aug-04-22 07:06PM] Sosei Heptares Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences [Aug-04-22 07:05PM] Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates [Aug-04-22 05:15PM] Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat? [Aug-04-22 05:00PM]
04-05-2022	PM	7:30 AM ET (May 4)	NBIX	Neurocrine Biosciences	8,599	0.14	0.33	0.00	Neurocrine Biosciences Non-GAAP EPS of $0.30 misses by $0.29, revenue of $310.6M beats by $6.53M; reaffirms FY22 guidance [5/4/2022 7:33 AM]	88.26	-0.44 (-0.50%)	88.70	0.0 (0.00%)	71.88 - 108.02	1,331,282	650,000	8,423
Neurocrine Biosciences Q1 2022 Earnings Preview [5/3/2022 2:24 PM] Neurocrine Biosciences Non-GAAP EPS of $0.30 misses by $0.29, revenue of $310.6M beats by $6.53M; reaffirms FY22 guidance [5/4/2022 7:33 AM] Neurocrine Biosciences to Present at the Bank of America Securities 2022 Healthcare Conference [May-03-22 04:01PM] Neurocrine Biosciences Reports First Quarter 2022 Financial Results and Reiterates 2022 Financial Guidance [May-04-22 07:30AM] Is Neurocrine Biosciences (NASDAQ:NBIX) A Risky Investment? [May-04-22 08:04AM] Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates [May-04-22 08:45AM]
11-02-2022	PM	8:25 AM ET (Feb 11)	NBIX	Neurocrine Biosciences, Inc.	7,580	-0.08	0.61	3.58	Neurocrine Biosciences Non-GAAP EPS of $0.04 misses by $0.84, revenue of $312M misses by $5.72M [2/11/2022 7:39 AM]	85.57	5.97 (7.50%)	80.50	0.90 (1.13%)	71.88 - 119.21	1,878,613	910,000	41,377
Neurocrine Biosciences Q4 2021 Earnings Preview [2/10/2022 11:58 AM] Neurocrine Biosciences Non-GAAP EPS of $0.04 misses by $0.84, revenue of $312M misses by $5.72M [2/11/2022 7:39 AM] Neurocrine spikes to record biggest gain in 10 months despite quarterly miss [2/11/2022 11:30 AM] Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2021 Financial Results and Provides Financial Expectations for Fiscal 2022 [Feb-11-22 07:30AM] Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates [Feb-11-22 08:45AM]
01-11-2021	AH	4:00 PM ET (Nov 1)	NBIX	Neurocrine Biosciences, Inc.	9,640	0.23	0.51	-0.62	Neurocrine Biosciences EPS misses by $0.16, misses on revenue [11/1/2021 4:14 PM]	95.55	-10.67 (-10.05%)	98.02	-8.20 (-7.72%)	84.77 - 120.27	2,694,238	620,000	6,708
Neurocrine Biosciences EPS misses by $0.16, misses on revenue [11/1/2021 4:14 PM] Neurocrine swings to Q3 2021 profit, but EPS falls below expectations; shares down 6% [11/1/2021 4:36 PM] Neurocrine defended by analysts despite Q3 miss [11/2/2021 12:48 PM] Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021 [Nov-01-21 08:00AM] Neurocrine Biosciences Reports Third Quarter 2021 Financial Results [Nov-01-21 04:01PM] Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates [Nov-01-21 05:15PM] Neurocrine Biosciences, Inc (NBIX) Q3 2021 Earnings Call Transcript [Nov-01-21 10:00PM] Why Neurocrine Biosciences Shares Fell Nearly 10% Today [Nov-02-21 03:14PM]
03-08-2021	AH	4:00 PM ET (Aug 3)	NBIX	Neurocrine Biosciences, Inc.	8,810	0.43	0.52	0.81	Neurocrine Biosciences EPS misses by $0.13, beats on revenue [8/3/2021 4:04 PM]	93.20	-4.50 (-4.61%)	93.20	0.0 (0.00%)	86.02 - 126.71	1,582,172	710,000	13,859
Neurocrine Biosciences EPS misses by $0.13, beats on revenue [8/3/2021 4:04 PM] Neurocrine Biosciences Reports Second Quarter 2021 Financial Results [Aug-03-21 04:01PM] Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates [Aug-03-21 05:25PM] Neurocrine Biosciences, inc (NBIX) Q2 2021 Earnings Call Transcript [Aug-03-21 10:31PM]
05-05-2021	AH	4:00 PM ET (May 5)	NBIX	Neurocrine Biosciences, Inc.	8,930	0.33	0.47	0.82	Neurocrine Biosciences EPS misses by $0.24, misses on revenue [5/5/2021 4:02 PM]	89.43	-2.17 (-2.37%)	89.43	0.0 (0.00%)	86.02 - 136.26	1,322,071	650,000	6,415
Neurocrine upgraded at Barclays despite Q1 earnings miss [5/6/2021 11:02 AM] Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference [May-04-21 04:01PM] Neurocrine Biosciences, Inc. to Host Earnings Call [May-05-21 02:45PM] Neurocrine Biosciences Reports First Quarter 2021 Financial Results [May-05-21 04:01PM] Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates [May-05-21 05:15PM] Neurocrine Biosciences Inc (NBIX) Q1 2021 Earnings Call Transcript [May-06-21 12:01AM] Is Neurocrine Biosciences (NASDAQ:NBIX) Using Too Much Debt? [May-06-21 06:14AM]
04-02-2021	AH	4:00 PM ET (Feb 4)	NBIX	Neurocrine Biosciences, Inc.	10,600	3.58	0.59	0.35	Neurocrine Biosciences EPS beats by $0.01, misses on revenue [2/4/2021 4:05 PM]	116.27	1.72 (1.50%)	113.75	-0.80 (-0.70%)	72.14 - 136.26	948,528	875,452	28,753
Neurocrine Biosciences EPS beats by $0.01, misses on revenue [2/4/2021 4:05 PM] More info. on Neurocrine Biosciences Q4 earnings [2/5/2021 3:29 PM] Neurocrine’s revenue miss: Baird expects a rebound in 2021 [2/5/2021 3:40 PM]
09-11-2020	AH	4:00 PM ET (Nov 9)	NBIX	Neurocrine Biosciences, Inc.	9,360	-0.62	0.11	0.79	Neurocrine Biosciences EPS misses by $0.28, misses on revenue, FY outlook [11/9/2020 4:04 PM]	87.61	-15.20 (-14.78%)	90.43	-12.38 (-12.04%)	72.14 - 136.26	3,461,074	1,012,250	12,539

03-08-2020	AH	4:00 PM ET (Aug 3)	NBIX	Neurocrine Biosciences, Inc.	11,300	0.81	0.65	0.37	Neurocrine Biosciences EPS beats by $0.40, beats on revenue [8/3/2020 4:02 PM]	120.56	-2.45 (-1.99%)	124.50	1.49 (1.21%)	72.14 - 136.26	1,018,573	641,202	5,440

06-05-2020	AH		NBIX	Neurocrine Biosciences, Inc.	9,220	0.82	0.55	-1.12		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0